Clinical Trial Update: Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 study evaluating activity, safety, and pharmacokinetics of a therapy in pediatric patients with moderate to severe chronic graft-versus-host disease aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Not disclosed

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft vs Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-04-17